source
- Eli Lilly’s $3.8 billion acquisition of AtaiBeckley signals strong backing for psychedelic therapeuticsNovartis and Roche kicked off the second‑quarter earnings season, with other majors such as AstraZeneca, GSK and Biogen slated to follow. The earnings wave highlights continued revenue growth acros…
- FDA approves Merck’s oral PCSK9 inhibitor Lipfendra, but cardiologists question its immediate impactThe FDA has granted approval to enlicitide, marketed by Merck as Lipfendra, marking the first oral PCSK9 inhibitor for lowering blood cholesterol. The drug arrives as new clinical guidelines encou…